Clinical Trials Logo

Clinical Trial Summary

Transurethral resection of the prostate (TURP) is a common and standard urological surgical procedure for managing benign prostatic hyperplasia (BPH). Although surgical technology improved in recent decades, severe complications such as TURP syndrome, hematuria, and postoperative hemorrhage were still considerable. Coagulopathy is one of rare but devastating complication which may contribute to bleeding during and after TURP. Although the exact pathophysiological condition of coagulopathy is not clear, there are several possible mechanisms of TURP associated coagulopathy including: urokinase- (u-PA) and tissue-type plasminogen activator (t-PA)-related fibrinolysis; absorption of irrigating fluid associated dilutional coagulopathy; release of prostatic particles rich in tissue thromboplastins into the circulation causing secondary fibrinolysis and disseminated intravascular coagulopathy (DIC); sepsis with DIC associated with bacteria entering the circulation due to prostatic venous sinuses opening and the using of high pressure irrigation. On the other hand, platelet are essential to hemostasis and thrombosis and its activation also contributes to leukocyte recruitment and DIC. Furthermore, previous studies demonstrated that activated platelets could express TLR4, CD40L, P-selectin and induce platelet-leukocyte aggregation (PLA), which were considered important for systemic inflammatory responses and DIC development. Currently, no study investigating the association of prostate particle and platelet activation. Here, we tested the hypothesis that prostate tissue may induce inflammatory responses through platelet activation by measuring the expression of TLR4, CD40L, P-selectin and PLA on platelets.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05059431
Study type Observational
Source Tri-Service General Hospital
Status Completed
Start date February 4, 2015
Completion date April 24, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT05017285 - Ejaculation Preservation After Laser Enucleation Prostate N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT03176017 - Ejaculatory Sparing Transurethral Incision Of The Prostate (ES-TUIP) Versus Conventional TUIP N/A
Completed NCT02244294 - FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH) Phase 2
Recruiting NCT03966950 - Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia N/A
Completed NCT04781985 - Prostatic Resection Cavity Stone Post Transurethral Resection of the Prostate (TURP). A Rare Case Scenario N/A
Not yet recruiting NCT01876836 - Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Phase 4
Recruiting NCT04580628 - Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)
Completed NCT04848181 - The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate Early Phase 1
Recruiting NCT04781049 - Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial N/A
Completed NCT04275076 - HoLEP Vs BPEP for Large Prostatic Adenoma Phase 3
Recruiting NCT05023824 - Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH Phase 3
Not yet recruiting NCT04514718 - Low Energy HoLEP on IPSS N/A
Active, not recruiting NCT03600766 - Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study Phase 2
Active, not recruiting NCT03131544 - MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH) N/A